HEPA
Hepion Pharmaceuticals, Inc.
Hepion Pharmaceuticals, Inc. (HEPA) has 4 SEC Form 4 filings (5 transaction rows) in the rolling window, disclosed by 4 distinct insiders. Most recent filing: Apr 27, 2026.
Insiders have net bought $400K over the trailing 6 months.
- Industry:Biotechnology
- CEO:Gary S. Stetz
- Employees:22
- HQ:Edison, NJ, US
- IPO:2014-02-10
Insider Buying
$400K
reported purchases (SEC code P)
Insider Selling
$0
reported sales (SEC code S)
Unique Insiders
4
in the rolling window
Market Cap
$1.5M
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
Purcell Michael J.First filing | Director | Purchase | 1,250,000 | $50K | Apr 27 | SEC ↗ |
LoPriore Vincent SFirst filing | Executive Chairman | Purchase | 6,250,000 | $250K | Apr 27 | SEC ↗ |
Appajosyula SireeshFirst filing | Director | Purchase | 1,250,000 | $50K | Apr 27 | SEC ↗ |
Stetz Gary S.First filing | Interim CEO | Purchase | 1,250,000 | $50K | Apr 27 | SEC ↗ |
Related companies
Hepion Pharmaceuticals, Inc. is in the Healthcare sector.